Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Marijuana use not linked to eGFR changes, albuminuria

13 Nov 2017

High levels of marijuana exposure appears to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.

The researchers recruited 3,765 adolescents with preserved eGFR and whose cystatin C levels and urinary albumin-to-creatinine ratios were measured at defined intervals. Marijuana use was assessed at defined intervals using a self-administered questionnaire.

Over the 10-year follow-up, 83 percent (n=3,131) of the participants reported either past or current marijuana use, with the mean eGFRcys measured to be 111 mL/min per 1.73 m2. Throughout the duration of the study, the proportion of current marijuana use remained above 15 percent.

Participants with at least 5 years of marijuana use had significantly lower eGFRcys, according to a multivariable analysis adjusted for age, race, sex, employment status, comorbidities and other clinical factors (percent difference, -3.0; 95 percent CI, -5.6 to -0.4; p=0.03).

While the trend between greater marijuana use and lower eGFRcys was statistically significant in the overall sample (p=0.04) and when stratified by race (p=0.03), no dose-response relationship was observed.

In contrast, marijuana use, even in those with at least 5 years of use, was not associated with 5-year changes in eGFRcys, both from years 10 to 15 and 15 to 20 (p=0.82 for trend).

Similarly, both rapid declines in eGFRcys (p=0.66 for trend) and prevalent albuminuria (p=0.41 for trend) were not associated with higher levels of marijuana use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.